Pancreatic Neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
Collectively, these findings reveal a highly dynamic and interdependent metabolic, transcriptional, and epigenetic regulatory network governed by Yap, Myc, Sox2, and p53 that dictates pancreatic tumor metabolism, growth, survival, and differentiation.
|
31447265 |
2019 |
Pancreatic Neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
Supernumerary and abnormal centrosomes are observed in the earliest stages of pancreatic tumor development, and the p53 pathway acts as an initial barrier to the proliferation of cells with extra centrosomes.
|
29491046 |
2018 |
Pancreatic Neoplasm
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Among other somatic mutations, TP53 is mutated in more than 75% of human pancreatic tumors.
|
29367463 |
2018 |
Pancreatic Neoplasm
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
Stat3, Il6st (encodes gp130), or Trp53 were disrupted, or a mutant form of P53 (P53R172H) or transgenic sgp130 were expressed, in mice that developed pancreatic tumors resulting from expression of activated KRAS (KrasG12D, KC mice).
|
27003603 |
2016 |
Pancreatic Neoplasm
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Owing to the high incidence of p53 mutations in PanIN 3 lesions and pancreatic tumors, we interrogated the comparative ability of adult pancreatic acinar and ductal cells to respond to oncogenic Kras and mutant Tp53(R172H) using Hnf1b:CreER(T2) and Mist1:CreER(T2) mice.
|
26592447 |
2016 |
Pancreatic Neoplasm
|
0.900 |
Biomarker
|
disease |
CTD_mouse |
Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.
|
26390243 |
2015 |
Pancreatic Neoplasm
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
One out of seven Tsc1 (-/-) ; p53 (-/-) animals developed pancreatic tumors showing a distinctive tumor morphology, reminiscent of human ACC.
|
26683340 |
2015 |
Pancreatic Neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations.
|
24875860 |
2014 |
Pancreatic Neoplasm
|
0.900 |
Biomarker
|
disease |
CTD_mouse |
Functions of TAp63 and p53 in restraining the development of metastatic cancer.
|
23873029 |
2014 |
Pancreatic Neoplasm
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Surprisingly, little is known about the role and regulation of hdm2 in pancreatic tumors, a large proportion (50-75%) of which contain mutant p53.
|
19029954 |
2009 |
Pancreatic Neoplasm
|
0.900 |
AlteredExpression
|
disease |
LHGDN |
Surprisingly, little is known about the role and regulation of hdm2 in pancreatic tumors, a large proportion (50-75%) of which contain mutant p53.
|
19029954 |
2009 |
Pancreatic Neoplasm
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
Collectively, our results show that decreased MGMT expression is correlated with p53 activation, and significantly reduced primary pancreatic tumor growth.
|
19789303 |
2009 |
Pancreatic Neoplasm
|
0.900 |
GeneticVariation
|
disease |
LHGDN |
Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations.
|
18701504 |
2008 |
Pancreatic Neoplasm
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, the identical nucleotide mutation of TP53 gene was observed from both the endometrial and pancreatic tumors.
|
18577117 |
2008 |
Pancreatic Neoplasm
|
0.900 |
GeneticVariation
|
disease |
LHGDN |
Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer.
|
17659731 |
2007 |
Pancreatic Neoplasm
|
0.900 |
GeneticVariation
|
disease |
LHGDN |
Pancreatic tumor cell lines, CRL1420, which contains elevated levels of mutant p53, and CRL1682, with no detectable p53 protein, were stably transfected with the exogenous wild-type p53 gene.
|
17651038 |
2007 |
Pancreatic Neoplasm
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development.
|
17911264 |
2007 |
Pancreatic Neoplasm
|
0.900 |
AlteredExpression
|
disease |
LHGDN |
Expression of Gadd45a and p53 proteins in human pancreatic cancer: potential effects on clinical outcomes.
|
17230496 |
2007 |
Pancreatic Neoplasm
|
0.900 |
GeneticVariation
|
disease |
LHGDN |
Detecting low-abundance p16 and p53 mutations in pancreatic juice using a novel assay: heteroduplex analysis of limiting dilution PCRs.
|
17106238 |
2006 |
Pancreatic Neoplasm
|
0.900 |
GeneticVariation
|
disease |
LHGDN |
Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy.
|
15846069 |
2005 |
Pancreatic Neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
This suggests that LKB1-induced apoptosis is p53 independent but might be p73-mediated in the pancreatic tumor cell line, AsPC-1.
|
14511408 |
2004 |
Pancreatic Neoplasm
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
This study was undertaken to evaluate the impact of wild-type or mutant p53 status on the synergistic effects of 5-Fluorouracil (5-FU) and radiation (XRT) in pancreatic tumors.
|
12014658 |
2002 |
Pancreatic Neoplasm
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Gene therapy approaches involving p53 replacement are promising due to the central role of p53 in the cellular response to DNA damage and the high incidence of p53 mutations in pancreatic tumors.
|
10505853 |
1999 |
Pancreatic Neoplasm
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Both K-ras and p53 gene mutations are found commonly in pancreatic tumors.
|
10217065 |
1999 |
Pancreatic Neoplasm
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
Reduced expression of p53 and cyclin A in intraductal mucin-hypersecreting neoplasm of the pancreas compared with usual pancreatic ductal adenocarcinoma.
|
10445560 |
1999 |